Annual EBITDA
-$112.30 M
-$9.49 M-9.23%
December 31, 2023
Summary
- As of February 27, 2025, STOK annual EBITDA is -$112.30 million, with the most recent change of -$9.49 million (-9.23%) on December 31, 2023.
- During the last 3 years, STOK annual EBITDA has fallen by -$60.15 million (-115.32%).
- STOK annual EBITDA is now -1964.03% below its all-time high of -$5.44 million, reached on December 31, 2017.
Performance
STOK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$29.46 M
-$669.00 K-2.32%
September 30, 2024
Summary
- As of February 27, 2025, STOK quarterly EBITDA is -$29.46 million, with the most recent change of -$669.00 thousand (-2.32%) on September 30, 2024.
- Over the past year, STOK quarterly EBITDA has dropped by -$2.87 million (-10.78%).
- STOK quarterly EBITDA is now -1467.18% below its all-time high of -$1.88 million, reached on March 31, 2018.
Performance
STOK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$115.03 M
-$2.87 M-2.56%
September 30, 2024
Summary
- As of February 27, 2025, STOK TTM EBITDA is -$115.03 million, with the most recent change of -$2.87 million (-2.56%) on September 30, 2024.
- Over the past year, STOK TTM EBITDA has dropped by -$5.12 million (-4.66%).
- STOK TTM EBITDA is now -6018.51% below its all-time high of -$1.88 million, reached on March 31, 2018.
Performance
STOK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
STOK EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -9.2% | -10.8% | -4.7% |
| 3 y3 years | -115.3% | -10.8% | -4.7% |
| 5 y5 years | -793.6% | -10.8% | -4.7% |
STOK EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -32.0% | at low | -22.3% | +9.8% | -35.2% | +0.8% |
| 5 y | 5-year | -218.8% | at low | -169.6% | +9.8% | -226.5% | +0.8% |
| alltime | all time | -1964.0% | at low | -1467.2% | +9.8% | -6018.5% | +0.8% |
Stoke Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$29.46 M(+2.3%) | -$115.03 M(+2.6%) |
| Jun 2024 | - | -$28.79 M(+3.5%) | -$112.16 M(-3.3%) |
| Mar 2024 | - | -$27.81 M(-4.0%) | -$116.02 M(+3.3%) |
| Dec 2023 | -$112.30 M(+9.2%) | -$28.96 M(+8.9%) | -$112.30 M(+2.2%) |
| Sep 2023 | - | -$26.60 M(-18.5%) | -$109.91 M(-0.1%) |
| Jun 2023 | - | -$32.65 M(+35.5%) | -$110.07 M(+7.5%) |
| Mar 2023 | - | -$24.09 M(-9.3%) | -$102.36 M(-0.4%) |
| Dec 2022 | -$102.81 M(+20.8%) | -$26.57 M(-0.7%) | -$102.81 M(+2.3%) |
| Sep 2022 | - | -$26.76 M(+7.3%) | -$100.53 M(+4.5%) |
| Jun 2022 | - | -$24.94 M(+1.6%) | -$96.20 M(+3.4%) |
| Mar 2022 | - | -$24.55 M(+1.1%) | -$93.05 M(+9.4%) |
| Dec 2021 | -$85.09 M | -$24.29 M(+8.3%) | -$85.09 M(+13.2%) |
| Sep 2021 | - | -$22.43 M(+3.0%) | -$75.15 M(+13.5%) |
| Jun 2021 | - | -$21.78 M(+31.3%) | -$66.20 M(+15.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$16.59 M(+15.6%) | -$57.20 M(+9.7%) |
| Dec 2020 | -$52.16 M(+48.1%) | -$14.35 M(+6.5%) | -$52.16 M(+7.0%) |
| Sep 2020 | - | -$13.48 M(+5.4%) | -$48.74 M(+8.4%) |
| Jun 2020 | - | -$12.79 M(+10.8%) | -$44.98 M(+11.0%) |
| Mar 2020 | - | -$11.54 M(+5.6%) | -$40.53 M(+15.0%) |
| Dec 2019 | -$35.23 M(+180.3%) | -$10.93 M(+12.5%) | -$35.23 M(+22.5%) |
| Sep 2019 | - | -$9.72 M(+16.5%) | -$28.77 M(+29.0%) |
| Jun 2019 | - | -$8.34 M(+33.6%) | -$22.30 M(+31.7%) |
| Mar 2019 | - | -$6.24 M(+39.7%) | -$16.93 M(+34.7%) |
| Dec 2018 | -$12.57 M(+131.0%) | -$4.47 M(+37.3%) | -$12.57 M(+55.1%) |
| Sep 2018 | - | -$3.25 M(+9.6%) | -$8.10 M(+67.1%) |
| Jun 2018 | - | -$2.97 M(+57.8%) | -$4.85 M(+157.8%) |
| Mar 2018 | - | -$1.88 M | -$1.88 M |
| Dec 2017 | -$5.44 M | - | - |
FAQ
- What is Stoke Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Stoke Therapeutics?
- What is Stoke Therapeutics annual EBITDA year-on-year change?
- What is Stoke Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Stoke Therapeutics?
- What is Stoke Therapeutics quarterly EBITDA year-on-year change?
- What is Stoke Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Stoke Therapeutics?
- What is Stoke Therapeutics TTM EBITDA year-on-year change?
What is Stoke Therapeutics annual EBITDA?
The current annual EBITDA of STOK is -$112.30 M
What is the all time high annual EBITDA for Stoke Therapeutics?
Stoke Therapeutics all-time high annual EBITDA is -$5.44 M
What is Stoke Therapeutics annual EBITDA year-on-year change?
Over the past year, STOK annual EBITDA has changed by -$9.49 M (-9.23%)
What is Stoke Therapeutics quarterly EBITDA?
The current quarterly EBITDA of STOK is -$29.46 M
What is the all time high quarterly EBITDA for Stoke Therapeutics?
Stoke Therapeutics all-time high quarterly EBITDA is -$1.88 M
What is Stoke Therapeutics quarterly EBITDA year-on-year change?
Over the past year, STOK quarterly EBITDA has changed by -$2.87 M (-10.78%)
What is Stoke Therapeutics TTM EBITDA?
The current TTM EBITDA of STOK is -$115.03 M
What is the all time high TTM EBITDA for Stoke Therapeutics?
Stoke Therapeutics all-time high TTM EBITDA is -$1.88 M
What is Stoke Therapeutics TTM EBITDA year-on-year change?
Over the past year, STOK TTM EBITDA has changed by -$5.12 M (-4.66%)